AVN-211: Phase IIb started

Avineuro began a Russian Phase IIb trial to evaluate 4 and 8 mg AVN-211 once daily for 6 weeks in 80 patients with schizophrenia in a state of a partial remission on stable antipsychotic therapy. The ...